SPDL1 and familial pancreatic carcinoma: However, as pancreatic cancer with increased sPD-L1, including exoPD-L1, exhibits strong tumor T-cell infiltration, a combination of anti-PD-1/PD-L1 therapy with immunomodulating agents that inhibit immunosuppressive T cells, such as Tregs, may have clinical benefits.